The Clorox Company Earnings Cheat Sheet: Profit Falls, but Beats Forecasts
S&P 500 (NYSE:SPY) component The Clorox Company (NYSE:CLX) reported its results for the fourth quarter. Clorox Company manufactures consumer products that are sold primarily through mass merchandisers, grocery stores and other retail outlets.
The Clorox Company Earnings Cheat Sheet for the Fourth Quarter
Results: Net income for the housewares and accessories company fell to $169 million ($1.26 per share) vs. $171 million ($1.20 per share) a year earlier. This is a decline of 1.2% from the year earlier quarter.
Revenue: Rose 3.7% to $1.48 billion from the year earlier quarter.
Actual vs. Wall St. Expectations: CLX beat the mean analyst estimate of $1.19 per share. Analysts were expecting revenue of $1.47 billion.
Quoting Management: “I’m really pleased with our strong finish to fiscal year 2011,” said Chairman and CEO Don Knauss. “Despite the ongoing effects of the recession, we delivered very good results in the second half of the fiscal year, much as we’d been expecting, with sales increasing three percent, net earnings from continuing operations growing six percent, and diluted EPS from continuing operations up 11 percent. This solid performance was led by our portfolio of leading brands, which achieved its highest ever all-retail outlet market share of 27.9 percent, up 1.4 share points since fiscal 2008, the strongest performance of any branded player or private label in our categories.”
The company has now seen net income fall in each of the last three quarters. In the third quarter, net income fell 8.5% from the year earlier, while the figure fell 80.9% in the second quarter.
The company has now topped analyst estimates for the last three quarters. It beat the mark by one cent in the third quarter and by 6 cents in the second quarter.
Competitors to Watch: Zep, Inc. (NYSE:ZEP), The Procter & Gamble Co. (NYSE:PG), Church & Dwight Co., Inc. (NYSE:CHD), Colgate-Palmolive (NYSE:CL), Kimberly-Clark (NYSE:KMB), Ocean Bio-Chem, Inc. (NASDAQ:OBCI), PURE Bioscience (NASDAQ:PURE).
(Source: Xignite Financials)